Opyl Limited announced two major advances for Opin, a strategic partnership with Consentic, an online platform providing video-based electronic clinical trial consent (e-consent), and the launch of a new personalised research
screening service that will deliver improved trial enrolment and participant experience. The two new offerings will amplify Opin's current market-leading trial and study enrolment success rate. Together, these initiatives will enable strong revenue growth and scale in services as Opyl reaches for triple digit growth in the AUD 4.7 billion global clinical trial recruitment market. The key benefits to Opin in partnering with Consentic and offering expert research screening services, is in influencing and controlling the recruitment and enrolment value chain. Theadditional services are an advantage in capturing market share and customer acquisition, as well additional revenue growth. The expanded expert research screening service ensures participants are contacted directly, and triaged promptly, leading to higher enrolment, improved participant satisfaction, better value for customers and additional revenue for Opyl. Opin's goal is to deliver and most consistent enrolment rate of prequalified participants into trials and studies, compared to competitors. The agreement with Consentic is non-exclusive over two years during which time both companies will pitch the others' solution to existing and new customers. Each partner will receive revenue via a revenue-share (a fixed capped percentage of the project value) and referral fee arrangement.